Search

Your search keyword '"Inderson, Akin"' showing total 36 results
Start Over Author "Inderson, Akin" Publication Year Range Last 3 years
36 results on '"Inderson, Akin"'

1. Endoscopic ultrasonography-guided gastroenterostomy versus surgical gastrojejunostomy for palliation of malignant gastric outlet obstruction (ENDURO): study protocol for a randomized controlled trial

Author

Kastelijn, Janine B., van de Pavert, Yorick L., Besselink, Marc G., Fockens, Paul, Voermans, Rogier P., van Wanrooij, Roy L. J., de Wijkerslooth, Thomas R., Curvers, Wouter L., de Hingh, Ignace H. J. T., Bruno, Marco J., Koerkamp, Bas Groot, Patijn, Gijs A., Poen, Alexander C., van Hooft, Jeanin E., Inderson, Akin, Mieog, J. Sven D., Poley, Jan-Werner, Bijlsma, Alderina, Lips, Daan J., Venneman, Niels G., Verdonk, Robert C., van Dullemen, Hendrik M., Hoogwater, Frederik J. H., Frederix, Geert W. J., Molenaar, I. Quintus, Welsing, Paco M. J., Moons, Leon M. G., van Santvoort, Hjalmar C., and Vleggaar, Frank P.

Published
2023
Full Text
View/download PDF

3. Prediction of Biomarker Expression on Primary Pancreatic Ductal Adenocarcinoma Tissues Using Fine-Needle Biopsies: Paving the Way for a Patient-Tailored Molecular Imaging Approach

Author

Houvast, Ruben D., van Duijvenvoorde, Maurice, Chua, JiaXin, Vankemmelbeke, Mireille, Durrant, Lindy G., Inderson, Akin, van Hooft, Jeanin E., Mieog, J. Sven D., Bonsing, Bert A., Sier, Cornelis F. M., Crobach, A. Stijn L. P., Vahrmeijer, Alexander L., and Kuppen, Peter J. K.

Published
2023
Full Text
View/download PDF

4. Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis

Author

Klatte, Derk C.F., Boekestijn, Bas, Onnekink, Anke M., Dekker, Friedo W., van der Geest, Lydia G., Wasser, Martin N.J.M., Feshtali, Shirin, Mieog, J. Sven D., Luelmo, Saskia A.C., Morreau, Hans, Potjer, Thomas P., Inderson, Akin, Boonstra, Jurjen J., Vasen, Hans F.A., van Hooft, Jeanin E., Bonsing, Bert A., and van Leerdam, Monique E.

Published
2023
Full Text
View/download PDF

6. Overuse and Misuse of Antibiotics and the Clinical Consequence in Necrotizing Pancreatitis: An Observational Multicenter Study

Author

Timmerhuis, Hester C., van den Berg, Fons F., Noorda, Paula C., van Dijk, Sven M., van Grinsven, Janneke, Sperna Weiland, Christina J., Umans, Devica S., Mohamed, Yasmin A., Curvers, Wouter L., Bouwense, Stefan A.W., Hadithi, Muhammed, Inderson, Akin, Issa, Yama, Jansen, Jeroen M., de Jonge, Pieter Jan F., Quispel, Rutger, Schwartz, Matthijs P., Stommel, Martijn W.J., Tan, Adriaan C.I.T.L., Venneman, Niels G., Besselink, Marc G., Bruno, Marco J., Bollen, Thomas L., Sieswerda, Elske, Verdonk, Robert C., Voermans, Rogier P., and van Santvoort, Hjalmar C.

Published
2023
Full Text
View/download PDF

7. THU-115-YI Ursodeoxycholic acid treatment for primary sclerosing cholangitis

Author

Mol, Bregje, primary, van Munster, Kim, additional, Weersma, Rinse, additional, Inderson, Akin, additional, Boonstra, Kirsten, additional, Drenth, Joost PH, additional, van Meer, Suzanne, additional, de Vries, Elsemieke S., additional, Spanier, B.W. Marcel, additional, Vrij, Ton, additional, Verlaan, Tess, additional, van Duijn, Femke, additional, Ponsioen, Willemijn, additional, Beuers, Ulrich, additional, Dijkgraaf, Marcel, additional, and Ponsioen, Cyriel, additional

Published
2024
Full Text
View/download PDF

10. Surveillance for pancreatic cancer in high-risk individuals leads to improved outcomes: a propensity score matched analysis

Author

Klatte, Derk, primary, Boekestijn, Bas, additional, Onnekink, Anke, additional, Dekker, Friedo, additional, van der Geest, Lydia, additional, Wasser, Martin, additional, Feshtali, Shirin, additional, Mieog, Sven, additional, Luelmo, Saskia, additional, Morreau, Hans, additional, Potjer, Thomas, additional, Inderson, Akin, additional, Boonstra, Jurjen, additional, Vasen, Hans, additional, van Hooft, Jeanin, additional, Bonsing, Bert, additional, and van Leerdam, Monique, additional

Published
2023
Full Text
View/download PDF

11. Impact of nationwide implementation of best practices in pancreatic cancer care (PACAP-1): a stepped-wedge cluster randomised controlled trial

Author

Augustinus, Simone, primary, Mackay, Tara M., additional, Latenstein, Anouk E.J., additional, van der Geest, Lydia G., additional, Bogte, Auke, additional, Bonsing, Bert A., additional, Bos, Hendrik, additional, Bosscha, Koop, additional, Borsens, Lodewijk A.A., additional, Cirkel, Geert A., additional, Hol, Lieke, additional, Busch, Olivier R.C., additional, Creemers, Geert-Jan, additional, Curvers, Wouter L., additional, Derks, Sarah, additional, Dulk, Marcel den, additional, van Dieren, Susan, additional, van Driel, Lydi M.J.W., additional, Festen, Sebastiaan, additional, van Geenen, Erwin J.M., additional, de Groot, Derk-Jan A., additional, de Groot, Jan-Willem B., additional, Koerkamp, Bas Groot, additional, Mohammad, Nadia Haj, additional, Haberkorn, Brigitte C.M., additional, Haver, Joyce T., additional, van der Harst, Erwin, additional, Hemmink, G.J. Maarten, additional, de Hingh, Ignace H., additional, Hoge, Chantal, additional, Homs, Marjolein Y.V., additional, Inderson, Akin, additional, Jacobs, Maarten A.J.M., additional, Kerver, Emile D., additional, Liem, Mike S.L., additional, Los, Maartje, additional, Lubbinge, Hans, additional, Luelmo, Saskia A.C., additional, de Meijer, Vincent E., additional, Mekenkamp, Leonie, additional, Molenaar, I. Quintus, additional, Patijn, Gijs A., additional, Quispel, Rutger, additional, Römkens, Tessa E.H., additional, van Santvoort, Hjalmar C., additional, Schreinemakers, Jennifer M.J., additional, Schut, Heidi, additional, Seerden, Tom, additional, Stommel, Martijn W.J., additional, Venneman, Niels G., additional, Verdonk, Robert C., additional, Verheij, Joanne, additional, van Vilsteren, Frederike G.I., additional, de Vos-Geelen, Judith, additional, Vulink, Annelie, additional, Wientjes, Caroline A., additional, Wit, Fennie, additional, Wessels, Frank J., additional, Zonderhuis, Babs, additional, Henri van Werkhoven, C., additional, van Hooft, Jeanin E., additional, van Eijck, Casper H.J., additional, Wilmink, Johanna W., additional, van Laarhoven, Hanneke W.M., additional, and Besselink, Marc G., additional

Published
2023
Full Text
View/download PDF

13. Prospective multicentre study of indications for surgery in patients with idiopathic acute pancreatitis following endoscopic ultrasonography (PICUS)

Author

Umans, Devica S, primary, Timmerhuis, Hester C, additional, Anten, Marie-Paule G F, additional, Bhalla, Abha, additional, Bijlsma, Rina A, additional, Boxhoorn, Lotte, additional, Brink, Menno A, additional, Bruno, Marco J, additional, Curvers, Wouter L, additional, van Eijck, Brechje C, additional, Erkelens, G Willemien, additional, van Geenen, Erwin J M, additional, Hazen, Wouter L, additional, Hoge, Chantal V, additional, Hol, Lieke, additional, Inderson, Akin, additional, Kager, Liesbeth M, additional, Kuiken, Sjoerd D, additional, Perk, Lars E, additional, Quispel, Rutger, additional, Römkens, Tessa E H, additional, Sperna Weiland, Christina J, additional, Thijssen, Annemieke Y, additional, Venneman, Niels G, additional, Verdonk, Robert C, additional, van Wanrooij, Roy L J, additional, Witteman, Ben J, additional, Besselink, Marc G, additional, and van Hooft, Jeanin E, additional

Published
2023
Full Text
View/download PDF

14. Impact of Endoscopic Ultrasound in Unresectable Perihilar Cholangiocarcinoma patients in Liver Transplantation work-up

Author

de Jong, David M., primary, den Hoed, Caroline M., additional, Willemssen, Francois E.J.A., additional, Thomeer, Maarten G.J., additional, Bruno, Marco J., additional, Groot Koerkamp, Bas, additional, de Jonge, Jeroen, additional, Alwayn, Ian P.J., additional, van Hooft, Jeanin E., additional, Hoogwater, Frederik, additional, van der Heide, Frans, additional, Inderson, Akin, additional, van Vilsteren, Frederike G.I., additional, and van Driel, Lydi M.J.W., additional

Published
2023
Full Text
View/download PDF

15. Response

Author

Sissingh, Noor J., primary, de Vries, Boudewijn A., additional, Inderson, Akin, additional, van Hoek, Bart, additional, van der Heide, Frans, additional, and van Hooft, Jeanin E., additional

Published
2023
Full Text
View/download PDF

16. Endoscopic ultrasonography-guided gastroenterostomy versus surgical gastrojejunostomy for palliation of malignant gastric outlet obstruction (ENDURO): study protocol for a randomised controlled trial

Author

de Pavert, Yorick L. van, primary, Kastelijn, Janine B., additional, Besselink, Marc G., additional, Fockens, Paul, additional, Voermans, Rogier P., additional, Wanrooij, Roy L.J. van, additional, de Wijkerslooth, Thomas R., additional, Curvers, Wouter L., additional, de Hingh, Ignace H.J.T., additional, Bruno, Marco J., additional, Koerkamp, Bas Groot, additional, Patijn, Gijs A., additional, Poen, Alexander C., additional, Hooft, Jeanin E. van, additional, Inderson, Akin, additional, Mieog, J. Sven D., additional, Poley, Jan-Werner, additional, Bijlsma, Alderina, additional, Lips, Daan J., additional, Venneman, Niels G., additional, Verdonk, Robert C., additional, Dullemen, Hendrik M. van, additional, Hoogwater, Frederik J.H., additional, Frederix, Geert W.J., additional, Molenaar, I. Quintus, additional, Welsing, Paco M.J., additional, Moons, Leon M.G., additional, Santvoort, Hjalmar C. van, additional, and Vleggaar, Frank P., additional

Published
2023
Full Text
View/download PDF

17. Randomized Trial of Ciclosporin with 2-h Monitoring vs. Tacrolimus with Trough Monitoring in Liver Transplantation: DELTA Study

Author

Ruijter, Bastian N., primary, Inderson, Akin, additional, van den Berg, Aad P., additional, Metselaar, Herold J., additional, Dubbeld, Jeroen, additional, Tushuizen, Maarten E., additional, Porte, Robert J., additional, Polak, Wojciech, additional, van der Helm, Danny, additional, van Reeven, Marjolein, additional, Rodriguez-Girondo, Mar, additional, and van Hoek, Bart, additional

Published
2023
Full Text
View/download PDF

19. Comparison of pancreatic cancer outcomes diagnosed in surveillance and the general population: A propensity score-matched analysis.

Author

Klatte, Derk C.F., primary, Boekestijn, Bas, additional, Onnekink, Anke M., additional, Dekker, Friedo W., additional, van der Geest, Lydia G., additional, Wasser, Martin N.J.M.M., additional, Feshtali, Shirin, additional, Mieog, J. Sven D., additional, Morreau, Hans, additional, Potjer, Thomas P., additional, Inderson, Akin, additional, Boonstra, Jurjen J., additional, Vasen, Hans F.A., additional, Luelmo, Saskia, additional, van Hooft, Jeanin E., additional, Bonsing, Bert A., additional, and van Leerdam, Monique E., additional

Published
2023
Full Text
View/download PDF

20. Randomized Trial of Ciclosporin with 2-h Monitoring vs. Tacrolimus with Trough Monitoring in Liver Transplantation:DELTA Study

Author

Ruijter, Bastian N., Inderson, Akin, van den Berg, Aad P., Metselaar, Herold J., Dubbeld, Jeroen, Tushuizen, Maarten E., Porte, Robert J., Polak, Wojciech, van der Helm, Danny, van Reeven, Marjolein, Rodriguez-Girondo, Mar, van Hoek, Bart, Ruijter, Bastian N., Inderson, Akin, van den Berg, Aad P., Metselaar, Herold J., Dubbeld, Jeroen, Tushuizen, Maarten E., Porte, Robert J., Polak, Wojciech, van der Helm, Danny, van Reeven, Marjolein, Rodriguez-Girondo, Mar, and van Hoek, Bart

Abstract

Background and Aims: Previous trials comparing cyclosporine and tacrolimus after liver transplantation (LT) showed conflicting results. Most used trough monitoring for cyclosporine (C0), leading to less accurate dosing than with 2-h monitoring (C2). Only one larger trial compared C2 with tacrolimus based on trough level (T0) after LT, with similar treated biopsy-proven acute rejection (tBPAR) and graft loss, while a smaller trial had less tBPAR with C2 compared to T0. Therefore, it is still unclear which calcineurin inhibitor is preferred after LT. We aimed to demonstrate superior efficacy (tBPAR), tolerability, and safety of C2 or T0 after first LT. Methods: Patients after first LT were randomized to C2 or T0. tBPAR, patient-and graft survival, safety and tolerability were the main endpoints, with analysis by Fisher test, Kaplan–Meier survival analysis and log-rank test. Results: In intention-to treat analysis 84 patients on C2 and 85 on T0 were included. Cumulative incidence of tBPAR C2 vs. T0 was 17.7% vs. 8.4% at 3 months (p=0.104), and 21.9% vs. 9.7% at 6 and 12 months (p=0.049). One-year cumulative mortality C2 vs. T0 was 15.5% vs. 5.9% (p=0.049) and graft loss 23.8% vs. 9.4% (p=0.015). Serum triglyceride and LDL-cholesterol was lower with T0 than with C2. Incidence of diarrhea in T0 vs, C2 was 64% vs. 31% (p≤0.001), with no other differences in safety and tolerability. Conclusions: In the first year after LT immunosuppression with T0 leads to less tBPAR and better patient-/re-transplant-free survival as compared to C2.

Published
2023

21. Endoscopic ultrasonography-guided gastroenterostomy versus surgical gastrojejunostomy for palliation of malignant gastric outlet obstruction (ENDURO):study protocol for a randomized controlled trial

Author

Kastelijn, Janine B., van de Pavert, Yorick L., Besselink, Marc G., Fockens, Paul, Voermans, Rogier P., van Wanrooij, Roy L.J., de Wijkerslooth, Thomas R., Curvers, Wouter L., de Hingh, Ignace H.J.T., Bruno, Marco J., Koerkamp, Bas Groot, Patijn, Gijs A., Poen, Alexander C., van Hooft, Jeanin E., Inderson, Akin, Mieog, J. Sven D., Poley, Jan Werner, Bijlsma, Alderina, Lips, Daan J., Venneman, Niels G., Verdonk, Robert C., van Dullemen, Hendrik M., Hoogwater, Frederik J.H., Frederix, Geert W.J., Molenaar, I. Quintus, Welsing, Paco M.J., Moons, Leon M.G., van Santvoort, Hjalmar C., Vleggaar, Frank P., Kastelijn, Janine B., van de Pavert, Yorick L., Besselink, Marc G., Fockens, Paul, Voermans, Rogier P., van Wanrooij, Roy L.J., de Wijkerslooth, Thomas R., Curvers, Wouter L., de Hingh, Ignace H.J.T., Bruno, Marco J., Koerkamp, Bas Groot, Patijn, Gijs A., Poen, Alexander C., van Hooft, Jeanin E., Inderson, Akin, Mieog, J. Sven D., Poley, Jan Werner, Bijlsma, Alderina, Lips, Daan J., Venneman, Niels G., Verdonk, Robert C., van Dullemen, Hendrik M., Hoogwater, Frederik J.H., Frederix, Geert W.J., Molenaar, I. Quintus, Welsing, Paco M.J., Moons, Leon M.G., van Santvoort, Hjalmar C., and Vleggaar, Frank P.

Abstract

Background: Malignant gastric outlet obstruction (GOO) is a debilitating condition that frequently occurs in patients with malignancies of the distal stomach and (peri)ampullary region. The standard palliative treatment for patients with a reasonable life expectancy and adequate performance status is a laparoscopic surgical gastrojejunostomy (SGJ). Recently, endoscopic ultrasound-guided gastroenterostomy (EUS-GE) emerged as a promising alternative to the surgical approach. The present study aims to compare these treatment modalities in terms of efficacy, safety, and costs. Methods: The ENDURO-study is a multicentre, open-label, parallel-group randomized controlled trial. In total, ninety-six patients with gastric outlet obstruction caused by an irresectable or metastasized malignancy will be 1:1 randomized to either SGJ or EUS-GE. The primary endpoint is time to tolerate at least soft solids. The co-primary endpoint is the proportion of patients with persisting or recurring symptoms of gastric outlet obstruction for which a reintervention is required. Secondary endpoints are technical and clinical success, quality of life, gastroenterostomy dysfunction, reinterventions, time to reintervention, adverse events, quality of life, time to start chemotherapy, length of hospital stay, readmissions, weight, survival, and costs. Discussion: The ENDURO-study assesses whether EUS-GE, as compared to SGJ, results in a faster resumption of solid oral intake and is non-inferior regarding reinterventions for persistent or recurrent obstructive symptoms in patients with malignant GOO. This trial aims to guide future treatment strategies and to improve quality of life in a palliative setting. Trial registration: International Clinical Trials Registry Platform (ICTRP): NL9592. Registered on 07 July 2021.

Published
2023

22. Disease burden in primary sclerosing cholangitis in the Netherlands:A long-term follow-up study

Author

van Munster, Kim N., Mol, Bregje, Goet, Jorn C., van Munster, Sanne N., Weersma, Rinse K., de Vries, Annemarie C., van der Meer, Adriaan J., Inderson, Akin, Drenth, Joost P., van Erpecum, Karel J., Boonstra, Kirsten, Beuers, Ulrich, Dijkgraaf, Marcel G.W., Ponsioen, Cyriel Y., van Munster, Kim N., Mol, Bregje, Goet, Jorn C., van Munster, Sanne N., Weersma, Rinse K., de Vries, Annemarie C., van der Meer, Adriaan J., Inderson, Akin, Drenth, Joost P., van Erpecum, Karel J., Boonstra, Kirsten, Beuers, Ulrich, Dijkgraaf, Marcel G.W., and Ponsioen, Cyriel Y.

Abstract

Background & Aims: Primary sclerosing cholangitis (PSC) is a progressive, cholestatic liver disease which greatly impacts the lives of individuals. Burden of disease due to shortened life expectancy and impaired quality of life is ill-described. The aim of this study was to assess long-term disease burden in a large population-based registry with regard to survival, clinical course, quality adjusted life years (QALYs), medical consumption and work productivity loss. Methods: All PSC patients living in a geographically defined area covering ~50% of the Netherlands were included, together with patients from the three liver transplant centres. Survival was estimated by competing risk analysis. Proportional shortfall of QALYs during disease course was measured relative to a matched reference cohort using validated questionnaires. Work productivity loss and medical consumption were evaluated over time. Results: A total of 1208 patients were included with a median follow-up of 11.2 year. Median liver transplant-free survival was 21.0 years. Proportional shortfall of QALYs increased to 48% >25 years after diagnosis. Patients had on average 12.4 hospital contact days among which 3.17 admission days per year, annual medical costs were €12 169 and mean work productivity loss was 25%. Conclusions: Our data quantify for the first time disease burden in terms of QALYs lost, clinical events, medical consumption, costs as well as work productivity loss, and show that all these are substantial and increase over time.

Published
2023

23. Disease burden in primary sclerosing cholangitis in the Netherlands: A long-term follow-up study

Author

van Munster, Kim N., Mol, Bregje, Goet, Jorn C., van Munster, Sanne N., Weersma, Rinse K., de Vries, Annemarie C., van der Meer, Adriaan J., Inderson, Akin, Drenth, Joost P., van Erpecum, Karel J., Boonstra, Kirsten, Beuers, Ulrich, Dijkgraaf, Marcel G.W., Ponsioen, Cyriel Y., Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), and Gastroenterology & Hepatology

Subjects
disease burden, QALY, SDG 3 - Good Health and Well-being, PSC, work productivity loss, survival, medical costs
Abstract

Background & Aims: Primary sclerosing cholangitis (PSC) is a progressive, cholestatic liver disease which greatly impacts the lives of individuals. Burden of disease due to shortened life expectancy and impaired quality of life is ill-described. The aim of this study was to assess long-term disease burden in a large population-based registry with regard to survival, clinical course, quality adjusted life years (QALYs), medical consumption and work productivity loss. Methods: All PSC patients living in a geographically defined area covering ~50% of the Netherlands were included, together with patients from the three liver transplant centres. Survival was estimated by competing risk analysis. Proportional shortfall of QALYs during disease course was measured relative to a matched reference cohort using validated questionnaires. Work productivity loss and medical consumption were evaluated over time. Results: A total of 1208 patients were included with a median follow-up of 11.2 year. Median liver transplant-free survival was 21.0 years. Proportional shortfall of QALYs increased to 48% >25 years after diagnosis. Patients had on average 12.4 hospital contact days among which 3.17 admission days per year, annual medical costs were €12 169 and mean work productivity loss was 25%. Conclusions: Our data quantify for the first time disease burden in terms of QALYs lost, clinical events, medical consumption, costs as well as work productivity loss, and show that all these are substantial and increase over time.

Published
2023

24. Health-related quality of life in patients with primary sclerosing cholangitis

Author

Mol, Bregje, van Munster, Kim N., Bogaards, Johannes A., Weersma, Rinse K., Inderson, Akin, de Groof, E. Joline, Rossen, Noortje G.M., Ponsioen, Willemijn, Turkenburg, Maud, van Erpecum, Karel J., Poen, Alexander C., Spanier, B. W.Marcel, Beuers, Ulrich H.W., Ponsioen, Cyriel Y., Epidemiology and Data Science, AII - Infectious diseases, APH - Methodology, Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Gastroenterology and Hepatology, Graduate School, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, Tytgat Institute for Liver and Intestinal Research, CCA - Cancer Treatment and Quality of Life, and CCA - Cancer biology and immunology

Subjects
health-related quality of life, Hepatology, inflammatory bowel disease, post-transplant, primary sclerosing cholangitis, population-based cohort, repeated measurements
Abstract

Background & Aims: Data regarding health-related quality of life (HRQoL) in primary sclerosing cholangitis (PSC) are sparse and have only been studied cross-sectionally in a disease which runs a fluctuating and unpredictable course. We aim to describe HRQoL longitudinally by using repeated measurements in a population-based cohort. Methods: Every 3 months from May 2017 up to August 2020, patients received digital questionnaires at home. These included the EQ-5D, 5-D Itch, patient-based SCCAI and patient-based HBI. The SF-36, measuring HRQoL over eight dimensions as well as a physical component summary (PCS) and mental component summary (MCS) score, was sent annually. Data were compared with Dutch reference data and a matched IBD disease control from the population-based POBASIC cohort. Mixed-effects modelling was performed to identify factors associated with HRQoL. Results: Three hundred twenty-eight patients completed 2576 questionnaires. A significant reduction of small clinical relevance in several mean HRQoL scores was found compared with the Dutch reference population: 46.4 versus 48.0, p =.018 for PCS and 47.5 versus 50.5, p =.004 for MCS scores. HRQoL outcomes were significantly negatively associated with coexisting active IBD (PCS −12.2, p

Published
2023

25. Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up

Author

Klatte, Derk C.F., primary, Boekestijn, Bas, additional, Wasser, Martin N.J.M., additional, Feshtali Shahbazi, Shirin, additional, Ibrahim, Isaura S., additional, Mieog, J. Sven D., additional, Luelmo, Saskia A.C., additional, Morreau, Hans, additional, Potjer, Thomas P., additional, Inderson, Akin, additional, Boonstra, Jurjen J., additional, Dekker, Friedo W., additional, Vasen, Hans F.A., additional, van Hooft, Jeanin E., additional, Bonsing, Bert A., additional, and van Leerdam, Monique E., additional

Published
2022
Full Text
View/download PDF

26. Health-related quality of life in patients with primary sclerosing cholangitis: a longitudinal population-based cohort study

Author

Mol, Bregje, van Munster, Kim, Bogaards, Johannes, Weersma, Rinse, Inderson, Akin, de Groof, Joline, Rossen, Noortje, Ponsioen, Willemijn, Turkenburg, Maud, van Erpecum, Karel J., Poen, Alexander, Spanier, B. W. Marcel, Beuers, Ulrich, Ponsioen, Cyriel, Gastroenterology and hepatology, AII - Infectious diseases, Amsterdam Gastroenterology Endocrinology Metabolism, Medical oncology, and APH - Methodology

Published
2022

27. 249: PANCREATIC CANCER SURVEILLANCE IN CDKN2A MUTATION CARRIERS: YIELD AND OUTCOMES OF 20 YEARS PROSPECTIVE FOLLOW-UP

Author

Klatte, Derk, primary, Boekestijn, Bas, additional, Wasser, Martin, additional, Feshtali, Shirin Shahbazi, additional, Ibrahim, Isaura, additional, Mieog, J.S., additional, Luelmo, Saskia, additional, Morreau, Hans, additional, Potjer, Thomas, additional, Inderson, Akin, additional, Boonstra, Jurjen, additional, Dekker, Friedo, additional, Vasen, Hans F., additional, Hooft, Jeanin E. Van, additional, Bonsing, Bert A., additional, and Leerdam, Monique Van, additional

Published
2022
Full Text
View/download PDF

29. Motorized Spiral Enteroscopy: Multicenter prospective study on performance and safety including in patients with surgically-altered gastrointestinal anatomy

Author

Al-Toma, Abdulbaqi, Beaumont, Hanneke, Koornstra, Jan Jacob, van Boeckel, Petra, Hergelink, Dorien Oude, van de Kraan, Jolein, Inderson, Akin, de Ridder, Rogier, Jacobs, M A J M, Interne Geneeskunde, MUMC+: MA Maag Darm Lever (9), and RS: FHML non-thematic output

Abstract

BACKGROUND AND STUDY AIMS: Data are scarce on the efficacy and safety of the Motorized spiral enteroscopy (MSE). No data are available on the utility of this technique in patients with surgically-altered gastrointestinal (GI) anatomy. We aimed to evaluate the safety and efficacy of MSE in patients with suspected small-bowel disease including those with surgically-altered GI anatomy. METHODS: A multicenter prospective observational, uncontrolled study evaluated MSE in consecutive patients with suspected small-bowel pathology indicated for diagnostic and/or therapeutic intervention. RESULTS: A total of 170 patients (median age, 64 years; range 18-89 years; 102 male, 68 female) were included. The overall diagnostic yield was 64.1%. Endotherapy was performed in 53.5% of procedures. The median total procedure time for antegrade and retrograde approach was 45 minutes (IQR=30-80) and 40 (IQR=30-70) respectively. When total (pan-)enteroscopy was intended, this was achieved at rate of 70.3%, (28.1% by antegrade approach and 42.1% by a bi-directional approach). Surgically-altered GI anatomy was present in 34/170 (20%) of the all procedures and in 11/45 (24.4%) of the successful total enteroscopy procedures. Propofol sedation or general anesthesia were used in 92.9% and 7% of the procedures respectively. Minor adverse events were observed in 15.8% of patients, but no major adverse events. CONCLUSION: MSE seems to be effective and safe endoscopic procedure. Total (pan-)enteroscopy can be achieved, in one or two sessions, even in the presence of surgically-altered GI anatomy. The total procedure time is relatively short. For both antegrade and retrograde MSE procedures, propofol sedation seems sufficient and safe.

Published
2022

31. The performance and safety of motorized spiral enteroscopy, including in patients with surgically altered gastrointestinal anatomy: a multicenter prospective study

Author

Al-Toma, Abdulbaqi, additional, Beaumont, Hanneke, additional, Koornstra, Jan Jacob, additional, van Boeckel, Petra, additional, Hergelink, Dorien Oude, additional, van der Kraan, Jolein, additional, Inderson, Akin, additional, de Ridder, Rogier, additional, and Jacobs, Maarten, additional

Published
2022
Full Text
View/download PDF

32. IMPACT OF EUS-GUIDED CHOLEDOCHODUODENOSTOMY VERSUS TRANSPAPILLARY ENDOSCOPIC BILIARY DRAINAGE ON THE INTRA- AND POST-OPERATIVE OUTCOME OF PANCREATODUODENECTOMY: A MULTICENTER PROPENSITY SCORE MATCHED STUDY.

Author

Fritzsche, Jeska, de Jong, Mike, Bonsing, Bert, Busch, Olivier, Daams, Freek, van Delft, Foke, Derksen, Wouter, Erdmann, Joris, Festen, Sebastiaan, Fockens, Paul, Geenen, Erwin-Jan van, Inderson, Akin, Kazemier, Geert, Kuiken, Sjoerd D., Liem, Mike, Lips, Daan, Riele, Wouter te, Van Santvoort, Hjalmar, Siersema, Peter, and Venneman, Niels

Published
2024
Full Text
View/download PDF

33. Single fiber reflectance spectroscopy for pancreatic cancer detection during endoscopic ultrasound guided fine needle biopsy: a prospective cohort study

Author

van Manen, Labrinus, primary, Schmidt, Iris, additional, Inderson, Akin, additional, Houvast, Ruben D., additional, Boonstra, Jurjen J., additional, Dijkstra, Jouke, additional, van Hooft, Jeanin E., additional, Nagengast, Wouter B., additional, Robinson, Dominic J., additional, Vahrmeijer, Alexander L., additional, and Mieog, J. Sven D., additional

Published
2022
Full Text
View/download PDF

34. Pancreatic Cancer Surveillance in Carriers of a Germline Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up.

Author

Klatte, Derk C.F., Boekestijn, Bas, Wasser, Martin N.J.M., Feshtali Shahbazi, Shirin, Ibrahim, Isaura S., Mieog, J. Sven D., Luelmo, Saskia A.C., Morreau, Hans, Potjer, Thomas P., Inderson, Akin, Boonstra, Jurjen J., Dekker, Friedo W., Vasen, Hans F.A., van Hooft, Jeanin E., Bonsing, Bert A., and van Leerdam, Monique E.

Published
2022
Full Text
View/download PDF

36. Disease burden in primary sclerosing cholangitis in the Netherlands: A long-term follow-up study.

Author

van Munster KN, Mol B, Goet JC, van Munster SN, Weersma RK, de Vries AC, van der Meer AJ, Inderson A, Drenth JP, van Erpecum KJ, Boonstra K, Beuers U, Dijkgraaf MGW, and Ponsioen CY

Subjects
Humans, Follow-Up Studies, Quality of Life, Netherlands, Cost of Illness, Cholangitis, Sclerosing
Abstract

Background & Aims: Primary sclerosing cholangitis (PSC) is a progressive, cholestatic liver disease which greatly impacts the lives of individuals. Burden of disease due to shortened life expectancy and impaired quality of life is ill-described. The aim of this study was to assess long-term disease burden in a large population-based registry with regard to survival, clinical course, quality adjusted life years (QALYs), medical consumption and work productivity loss., Methods: All PSC patients living in a geographically defined area covering ~50% of the Netherlands were included, together with patients from the three liver transplant centres. Survival was estimated by competing risk analysis. Proportional shortfall of QALYs during disease course was measured relative to a matched reference cohort using validated questionnaires. Work productivity loss and medical consumption were evaluated over time., Results: A total of 1208 patients were included with a median follow-up of 11.2 year. Median liver transplant-free survival was 21.0 years. Proportional shortfall of QALYs increased to 48% >25 years after diagnosis. Patients had on average 12.4 hospital contact days among which 3.17 admission days per year, annual medical costs were €12 169 and mean work productivity loss was 25%., Conclusions: Our data quantify for the first time disease burden in terms of QALYs lost, clinical events, medical consumption, costs as well as work productivity loss, and show that all these are substantial and increase over time., (© 2022 The Authors. Liver International published by John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results